Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Comment by Investorpigson Jan 29, 2018 1:20am
255 Views
Post# 27452232

RE:RE:RE:RE:I admit, I'm confused!

RE:RE:RE:RE:I admit, I'm confused!
Rook14 wrote: I believe people are confused with this share conversion scenario because the shares of Cmed and ABC are not fixed until the merger is complete. Of course if you buy Cmed, then you know that side of the conversion. That is your fixed price for Cmed, but the price for ABC will continue to fluctuate and won't be fixed until the deal is finalized. The fact is you want ABC to be as high as possible, but if every one sells ABC, the share price will drop. 


I don't understand how people can be confused here. You simply divide the current cmed SP by 3.4. That will give your new buy in price for ACB. Simple. What's confusing to me is the action on Friday. IF you think this deal will close (seems very likely) ACB should be crashing and cmed spiking. If you were a long ACB holder you should be selling and buying into CMED so you can take advantage of the discount in conversion. If you can multiply ACBs current SP by 3.4 (at any point until this closes) and that number is greater than what CMEDs current SP is you're better to buy CMED. If you ever multiply ACBs SP by 3.4 and you find CMED is trading above that number you're better to buy into ACB directly. This is very simple math. What I'm confused about, based on that theory ABC should be dropping from everyone taking advantage of the current discount by buying into CMED causing CMED to spike. We saw the opposite to this Friday.
Bullboard Posts